SPONSOR EVENTS

Gold Sponsor Presentations

Throughout the Workshops and Scientific Sessions, you will have the opportunity to join a presentation hosted by one of our Gold Sponsors. Check back to this page often for updates.

Metabo-Profile Biotechnology (Shanghai) Co., Ltd.
Sponsor Studio (Workshop) 2.1

Tuesday, October 27 1:30 - 2:15 p.m. | Beijing

A Novel Metabolite Array Technology for Precision Medicine

The application of metabolomics in translational research suffers from several technological bottlenecks, such as data reproducibility issues and the lack of standardization of sample profiling procedures. Here, we report an automated high-throughput metabolite array technology that can rapidly and quantitatively determine 300 plus metabolites including fatty acids, amino acids, organic acids, carbohydrates and bile acids. Metabolite identification and quantification is achieved using the Targeted Metabolome Batch Quantification (TMBQ) software, the first cross-vendor data processing pipeline. With high detection efficiency and sensitivity in serum, urine, feces, cell lysates and liver tissue samples and suitable for different mass spectrometry systems, this metabolite array technology holds great potential for biomarker discovery and high throughput clinical testing. Additionally, data generated from such standardized procedures can be used to generate a clinical metabolomics database suitable for precision medicine in next-generation healthcare.

Bruker
Sponsor Studio (Workshop) 2.2

Tuesday, October 27 2:20 - 3:05 p.m. | Beijing

Australian National Phenome Centre and COVID-19 research network collaborating with Bruker to shed light on systemic metabolic disease

Join this workshop to learn more about how the Australian National Phenome Centre (ANPC) are tracking metabolic changes occurring during COVID -19 infection using a combined NMR and mass spectrometry approach. Learn how this unique approach gives a comprehensive characterisation and how it can be applied to tackle the ongoing global pandemic.

Waters Corporation
Sponsor Studio (Workshop) 3.1

Tuesday, October 27 10:00 - 10:45 a.m. | Paris

Measuring the metabolome: Using Cyclic IMS, Targeted pathway analysis, and novel chemistries to increase coverage, precision, and accuracy

Metabolomics and lipidomics gain interest as differentiated methodologies to reveal complexities of normal and pathological biology. The broad number and diversity of metabolites requires analytical instruments to provide accurate and precise data. Whether you are analyzing the global metabolome or specific classes of pathways, Waters has tools to ensure rigorous and reproducible quantitation whilst ion mobility offers exceptional coverage, confidence in identification and unique insights into molecular structure.

LECO Corporation
Sponsor Studio (Workshop) 3.2

Tuesday, October 27 10:50 - 11:35 | Paris

High Performance GC- and GCxGC-TOFMS Metabolomics-Based Approach for Discovery of Potential Biomarkers in Plasma

An elevated death rate exists for individuals with hepatocellular carcinoma (HCC). There is a critical need for the discovery of early stage HCC biomarkers to trigger rapid intervention and more effective medical treatment. Metabolomics is ideal for the investigation of cancer physiology and discovery of markers for disease diagnosis. The main objective of this study was to implement an untargeted analytical methodology for annotation of candidate cancer biomarkers in humans using GC-TOF MS and GCxGC-TOF MS techniques. In general, GC-TOF MS techniques resulted in excellent chromatographic resolution and expeditious sample characterization. GCxGC-high resolution (HR-)TOF MS was implemented for the identification of unknowns and confirmation of statistically significant metabolites. Plasma samples were treated with acetonitrile/isopropanol/water, centrifuged and supernatant materials were placed under vacuum to remove solvents. Dry samples were derivatized in two-steps: i) Methoximation and ii) silylation. Derivatized samples were injected into the chromatograph and separation performed using two columns with different separation mechanisms. Mass spectra were collected using an ion source temperature of 250°C, mass range of m/z 30 to 510 and an acquisition rate of 10 Hz, i.e. full spectra per second, (200 Hz for GCxGC). Data were processed using untargeted Peak Find and compounds were characterized through retention index filtering, similarity searches and formula determinations using accurate mass ions (HR-TOF MS). GCxGC-TOFMS processing resulted in composition maps (Contour plots) displaying wide variety of metabolites including acids, diacids, amino acids, fatty acids, bases, monosaccharides, disaccharides, sugar phosphates, sterols, nucleosides and others. Differentiation of the control and disease samples was performed through statistical processing of the data (e.g., XCMS). This work resulted in the identification of several candidate markers for HCC.

Biocrates Life Sciences Ag
Scientific Session 4.2

Wednesday, October 28 3:00 - 3:20 p.m. | Paris

Zoom onto your favorite metabolic pathway

Metabolomics and lipidomics studies not only require to be comprehensive; they also need to be reliable, reproducible, standardized, and quantitative. However, even when these attributes are met, such studies can only be informative when the analyses are coupled with the knowledge of the biological processes the measured metabolites are involved in. Here, we present the MxP® Quant 500 kit offering the broadest targeted metabolic pathway coverage with a quantitative multiplexed MS/MS analysis of up to 630 metabolites/lipids (26 analyte classes). Coupled with the MetaboINDICATORTM, an add on software tool, the kit can quickly translate the metabolomics/lipidomics data into knowledge by calculating additional 230 sums and ratios of the measured metabolites and lipids concentrations. These sums and ratios have the potential to identify immediate links and/or answers to pathway alterations to pathophysiological effects such as inflammation, gut barrier dysfunction or liver health. Examples of sums and ratios demonstrate the power of metabolic signatures providing new insights into metabolic disease development, potential biomarker development, and reference or cut-off data definition. The broad overall pathway analysis of the quantitative MxP® Quant 500 kit will be discussed in the context of hypothesis generation which is linked by zooming onto more specific pathway kit/assay solutions for hypothesis verification. Here we focus on the hot-topics of tryptophan and acylcarnitine metabolism and their relevance for immune modulation, gut-brain signaling (tryptophan) and mitochondrial health and energy homeostasis (acylcarnitines). In addition, we focus on the analytical sensitivity improvement and the expanded metabolite coverage strategies for pathway-specific kits/assays from the analytical point of view. Finally, we will highlight the relevance of metabolomics/lipidomics research and the suitability of the MxP® Quant 500 kit for comprehensive microbiome phenotyping and a more up to date topic around infectious diseases and Covid-19.

Human Metabolome Technologies
Scientific Session 4.3

Wednesday, October 28 3:25 - 3:45 p.m. | Paris

Novel One-stop Metabolomics Solutions for Biomarker Discovery

A biomarker discovery pipeline requires both targeted and untargeted metabolomics with a broad sweep of both polar and non-polar metabolites covering multiple pathways. Targeted quantitative metabolite panels are required when specific pathways are known or suspected. At Human Metabolome Technologies (HMT), we provide different metabolite profiling platforms so that our clients may approach both early discovery and validation studies using the most appropriate and cost-efficient methodologies with the most innovative technologies.At HMT our OMEGA SCAN plan combines ultra-high resolution using capillary electrophoresis to measure polar metabolites with high sensitivity Fourier transform mass spectrometry. OMEGA SCAN allows HMT to provide the widest representation of polar and charged metabolites using any type of sample from cells to tissues to biofluids. Our OMEGA SCAN Advanced option provides a specific protocol to measure and identify novel metabolites scanning all unannotated data, and our OMEGA SEARCH further supports the structural elucidation of such novel metabolites.In addition, our MEDIATOR SCAN plan provides targeted measurements of over 400 biologically significant complex lipids including fatty acids, acylcarnitines, ceramides, sphingomyelins, lysophospholipids, steroids eicosanoids and other oxylipins representing pathways that cross over multiple therapeutic studies including oxidative stress, immune response, lipid signaling, fatty acid synthesis, cholesterol/steroid signaling and inflammatory response. While MEDIATOR SCAN signals fatty acid biosynthesis and processing of long and very long chain fatty acids, OMEGA SCAN reports on over a hundred saturated or unsaturated and small or middle-chain fatty acids. Together multiple pathways can be examined and later validated with targeted assays, also developed by our fit-4-purpose assay development option.This combination of polar metabolite profiling using OMEGA SCAN or OMEGA SCAN Advanced with bioactive lipid profiling using MEDIATOR SCAN provides a powerful enabling technology platform producing large data sets of biological significance for biomarker discovery and targeted validation.

Thermo Fisher Scientific
Scientific Session 5.1

Wednesday, October 28 1:35 - 1:55 p.m. | New York

Exceptional Orbitrap performance enables robust quantitative metabolomics workflows

Metabolomics, the investigation of small molecules present in a biological system, finds application in diverse biomedical and industrial research. However, for metabolomics to provide valuable biological insights, robust reproducible measurements and confident metabolite identifications are required. Fast-scanning high resolution accurate mass spectrometers allow accurate mass assignments, resolving near mass isobaric species from complex mixtures, thus enabling confident compound identification and quantitation. Intelligent data acquisition algorithm, AcquireX, maximizes the number of metabolites interrogated by MS/MS, while minimizing the acquisition of fragmentation spectra from background and redundant signals. Here, we describe the development of robust metabolomics workflows utilizing a Thermo Scientific™ Orbitrap Exploris™ 240 mass spectrometer for the quantitation and confident annotation of polar metabolites and lipids in diverse biological matrices.Fast scanning rates and accurate mass measurements provided robust quantitation in the targeted analysis of amino acids. Ultra-high resolution aided elemental formula prediction and separation of isobars. AcquireX intelligent acquisition enabled efficient MS/MS sampling of more unique sample-relevant compounds resulting in fragmentation of more unique metabolites and a greater number of metabolites confidently annotated in human plasma (NIST SRM1950). The combination of high resolution accurate mass and intelligent acquisition enabled the development of a semi-targeted workflow for the simultaneous identification of knowns and structural elucidation of unknowns, that could lead to further biochemical insights in disease progression and treatment outcome. Excellent isotopic fidelity and enhanced fine structure at higher resolution, enabled the untargeted analysis of stable isotope labeling experiments providing accurate quantitation of 10% incorporation of 13C label, facilitating the elucidation of metabolic pathway associations. In summary, the new Orbitrap Exploris 240 mass spectrometer delivers robust high-quality data and its versatility enables all metabolomics applications, setting a new standard in metabolomics.

SCIEX
Scientific Session 5.3

Wednesday, October 28 2:25 - 2:45 p.m. | New York

Drug Metabolism Database: An Integrated Omics study to catalogue metabolic changes from 500 drugs, in 50 different cell lines over 5 years.

The mechanism of action of ~20% of FDA approved drugs is unknown. For many more off-target effects remain poorly described. Likewise, compounds orphaned for one indication might have an on or off-target effect that could benefit another indication in mono- or combination therapy. Given the impact, direct or indirect, of pharmaceuticals on metabolism, a curated integrated Omic database to catalogue the metabolic pathway impact of different reagents in different tissues is of significant potential value. With this idea in mind we started the project called Drug Metabolism Database (DMDB) which is an Integrated Omics study to catalogue metabolic changes from 500 drugs, in 500 different cell lines over 5 years. We recently launched the first version of DMDB which has integrative Omics (metabolomic, transcriptomic, fluxomic and phenomic) data from two cell lines (INS and C2C12) cultured overnight in the presence of 10 drugs targeting a wide variety of cellular and metabolic processes. To process data in DMDB we built the AIomic pipeline, an AI enabled integrative Omics pipeline. DMDB, in combination with AIomic, provides a unique platform to find succinct biological insights about drugs using a comprehensive view of metabolism and integration of Omics data, with speed and accuracy.

Metabolon
Scientific Session 6.2

Wednesday, October 28 5:00 - 5:20 p.m. | New York

Using Metabolomics to Understand Health and Disease

Metabolic derangements form the basis of any transition from homeostasis to disease, reflecting both genetic and non-genetic perturbations that drive alterations in health status. Metabolomics, the high-throughput profiling of changes in biochemical composition, is now recognized as a powerful tool to leverage both genetic and non-genetic information for providing unique insights into disease onset, progression and response to therapies. In large cohort studies, metabolomics is being used to correlate genotype and genomic variants with phenotypes, to identify the function of unknown genes and to functionally map genetic variants that modify the blood metabolome to identify drug targets and signatures of human disease. High-throughput biochemical profiling also reports on microbiome and environmental changes to provide a comprehensive view of deviation of a homeostatic state. Recent work reveals that microbiome activity, diet, and environment alter biochemical composition that has profound effects on disease onset, severity, and response to therapies that are not influenced by host genetics. As the market leader in the high throughput generation and interpretation of metabolomic data, Metabolon is leading global efforts to map human health through partnership with the world’s leading Population Health cohorts. The extensive knowledgebase built up from running over 1 million samples enables Metabolon to identify both beneficial and maladaptive signatures to help risk stratify populations. These population studies are integral to identifying disease signatures that can be applied to and advance precision medicine practices to assess disease risk and customize treatments. Taken together, comprehensive biochemical profiling will play a central role in a systems medicine approach to provide deep insights into disease mechanisms, stratify complex diseases into distinct clusters, expand our ability to identify drug targets, provide better tools to classify responders versus non-responders in clinical trials and generate metrics for assessing wellness